Experienced in Prothrombin Deficiency

Dr. Frank Y. Tsai

Honorhealth Ambulatory
Scottsdale, AZ
Experienced
in Prothrombin Deficiency
Specialties:Hematology Oncology | Oncology | Hematology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Frank Tsai is a Hematologist Oncology specialist and an Oncologist in Scottsdale, Arizona. Dr. Tsai and is rated as an Experienced provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Familial Pancreatic Cancer, Lung Cancer, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Tsai is currently accepting new patients.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in NY
Hospital Affiliations
Honorhealth Scottsdale Shea Medical Center
Honorhealth Scottsdale Thompson Peak Med Ctr
Honorhealth Scottsdale Osborn Medical Center
Honor Health John C. Lincoln Medical Center
Languages Spoken
English
Mandarin
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Oscar
  •  UnitedHealthcare
  •  Humana

Locations

HONORHEALTH AMBULATORY
10510 N 92nd St, Suite 200, Scottsdale, AZ 85258
480-323-1250

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Dose-Escalation Study of ADXS-NEO Expressing Personalized Tumor Antigens, Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 Dose-Escalation Study of ADXS-NEO Expressing Personalized Tumor Antigens, Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: February 24, 2023
Intervention Type: Biological
Study Phase: Phase 1
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma
A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced/Metastatic, Recurrent, Injectable Solid Tumors, With Emphasis on Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Cancer, Anaplastic Thyroid Carcinoma, and Cutaneous Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Biological
Study Drug: CDK-002
Study Phase: Phase 1/Phase 2
A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma
A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma
Enrollment Status: Unknown
Publish Date: December 23, 2022
Intervention Type: Drug
Study Drug: GZ17-6.02
Study Phase: Phase 1
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
A Phase 1/2a Study to Evaluate the Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine in Adult Patients With Selected Solid Tumors
Enrollment Status: Completed
Publish Date: April 19, 2022
Intervention Type: Drug, Biological
Study Drugs: GEN-009 Adjuvant Vaccine, Nivolumab, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oral Topotecan With HM30181A Monotherapy in Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: February 16, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men With Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: May 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer
An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: April 23, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
First-in-Human, Dose Finding, Open Label Phase 1A-1B Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: December 22, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 8 Less Clinical Trials

6 Total Publications

Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.
Journal: Investigational new drugs
Published: May 20, 2024
Similar Doctors
Expertise in
20
conditions
Dr. Hollis E. Shaw
Hematology Oncology | Hematology | Oncology
Expertise in
20
conditions
Dr. Hollis E. Shaw
Hematology Oncology | Hematology | Oncology
6335 E Main St, Suite C1, 
Mesa, AZ 
 (15.8 mi)
480-668-7060
Experience:
46+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Hollis Shaw is a Hematologist Oncology specialist and a Hematologist in Mesa, Arizona. Dr. Shaw has been practicing medicine for over 46 years and is rated as an Advanced provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Polycythemia Vera, Childhood Iron Deficiency Anemia, Congenital Antithrombin 3 Deficiency, and Hereditary Resistance to Anti-Vitamin K. Dr. Shaw is currently accepting new patients.

Expertise in
25
conditions
Dr. Michael A. Musci
Hematology Oncology | Hematology | Oncology
Expertise in
25
conditions
Dr. Michael A. Musci
Hematology Oncology | Hematology | Oncology

Ironwood Physicians PC

6111 E Arbor Ave, 
Mesa, AZ 
 (15.7 mi)
480-981-1326
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Musci is a Hematologist Oncology specialist and a Hematologist in Mesa, Arizona. Dr. Musci and is rated as an Advanced provider by MediFind in the treatment of Prothrombin Deficiency. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Familial Colorectal Cancer, and Lynch Syndrome. Dr. Musci is currently accepting new patients.

Expertise in
10
conditions
Dr. Leslie J. Padrnos
Hematology Oncology | Hematology | Oncology
Expertise in
10
conditions
Dr. Leslie J. Padrnos
Hematology Oncology | Hematology | Oncology

Mayo Clinic Arizona

5777 E Mayo Blvd, Mayo Clinic Hospital, 
Phoenix, AZ 
 (6.9 mi)
800-603-0558
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Leslie Padrnos is a Hematologist Oncology specialist and a Hematologist in Phoenix, Arizona. Dr. Padrnos and is rated as an Advanced provider by MediFind in the treatment of Prothrombin Deficiency. Her top areas of expertise are Myeloproliferative Neoplasms (MPN), Anemia, Thrombocytopenia, Essential Thrombocythemia, and Bone Marrow Aspiration. Dr. Padrnos is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile